Search for new biomarkers for prostate cancer using autoantibodies

2021 Fiscal Year Final Research Report

• Project/Area Number: 18K10051
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 58020:Hygiene and public health-related: including laboratory approach
• Research Institution: Kumamoto University
• Principal Investigator: Katoh Takahiko 熊本大学, 大学院生命科学研究部(医), 教授 (70169506)
• Project Period (FY): 2018-04-01 – 2022-03-31
• Keywords: 前立腺がん / 自己抗体 / セントロメア抗体

Outline of Final Research Achievements

Autoimmune diseases are characterized by the production of autoantibodies to various intercellular protein-nucleic acid complexes, protein complexes. In recent years, autoantibodies detected in patient serum have attracted attention as a new diagnostic marker for cancer. In this study, we measured serum autoantibodies against DFS70, Ro52, Ro60, CENP-A, CENP-B, which are presumed to be involved in the development of prostate cancer, as well as life style data, food intake frequency survey data, and clinical pathology. We integrated the data and conducted case-control study (673 cases of prostate cancer, 957 cases of health control group). Regarding CENP-A, the proportion was significantly lower in the cancer patient group, but no association was found between other autoantibodies and prostate cancer.

Free Research Field

公衆衛生学

Academic Significance and Societal Importance of the Research Achievements

近年のアレルギー性疾患の増加は周知の事実であるが、自己免疫疾患もまた増加しつつある。最新のデータによれば、すべての自己免疫疾患を合わせると、心臓病、がんに次いで３番目に罹患者が多く、その症状の深刻さを考えると原因解明と予防対策が喫緊の課題となっている。最近の研究によれば、腫瘍の診断マーカーとしてがん患者の血清に検出される自己抗体が注目されており、予防医学的・臨床的に重要な特異的バイオマーカーとなる可能性が期待されている。本研究では、自己抗体のがん発症における予防・臨床的意義を明らかにする。